BR112023001583A2 - Polipeptídeos de ss-glucocerebrosidase (gcase) modificado, polinucleotídeo, partícula viral e composição - Google Patents
Polipeptídeos de ss-glucocerebrosidase (gcase) modificado, polinucleotídeo, partícula viral e composiçãoInfo
- Publication number
- BR112023001583A2 BR112023001583A2 BR112023001583A BR112023001583A BR112023001583A2 BR 112023001583 A2 BR112023001583 A2 BR 112023001583A2 BR 112023001583 A BR112023001583 A BR 112023001583A BR 112023001583 A BR112023001583 A BR 112023001583A BR 112023001583 A2 BR112023001583 A2 BR 112023001583A2
- Authority
- BR
- Brazil
- Prior art keywords
- polynucleotide
- modified
- gcase
- viral particle
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2011813.9A GB202011813D0 (en) | 2020-07-29 | 2020-07-29 | Polypeptide |
| GBGB2100648.1A GB202100648D0 (en) | 2021-01-18 | 2021-01-18 | Polypeptide |
| GBGB2105924.1A GB202105924D0 (en) | 2021-04-26 | 2021-04-26 | Polypeptide |
| PCT/GB2021/051969 WO2022023761A2 (en) | 2020-07-29 | 2021-07-29 | Polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001583A2 true BR112023001583A2 (pt) | 2023-02-14 |
Family
ID=77265101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001583A BR112023001583A2 (pt) | 2020-07-29 | 2021-07-29 | Polipeptídeos de ss-glucocerebrosidase (gcase) modificado, polinucleotídeo, partícula viral e composição |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240261433A1 (https=) |
| EP (2) | EP4118200B1 (https=) |
| JP (1) | JP2023535808A (https=) |
| KR (1) | KR20230042513A (https=) |
| CN (1) | CN116322744A (https=) |
| AU (1) | AU2021316875B2 (https=) |
| BR (1) | BR112023001583A2 (https=) |
| CA (1) | CA3189801A1 (https=) |
| DK (1) | DK4118200T3 (https=) |
| ES (1) | ES3057448T3 (https=) |
| FI (1) | FI4118200T3 (https=) |
| HR (1) | HRP20251591T1 (https=) |
| IL (1) | IL299811A (https=) |
| MX (1) | MX2023001137A (https=) |
| PT (1) | PT4118200T (https=) |
| WO (1) | WO2022023761A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025122912A1 (en) | 2023-12-08 | 2025-06-12 | Denali Therapeutics Inc. | Modified glucocerebrosidase polypeptides and methods of use thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| CN118086341B (zh) * | 2024-04-25 | 2024-08-02 | 上海凌医生物科技有限公司 | 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框 |
| WO2026006173A1 (en) | 2024-06-24 | 2026-01-02 | Denali Therapeutics Inc. | Fusion proteins comprising modified glucocerebrosidase polypeptides and methods thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1775901A (en) * | 1999-11-17 | 2001-05-30 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| AU2352201A (en) * | 1999-12-30 | 2001-07-16 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| EP2154969B1 (en) | 2007-05-16 | 2015-11-18 | The Brigham and Women's Hospital, Inc. | Treatment of synucleinopathies |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| SI2638152T1 (sl) * | 2010-11-08 | 2016-12-30 | Amicus Therapeutics, Inc. | Variantni in rekombinantni proteini beta-glukocerebrozidaze s povišano stabilnostjo in povišano ohranjeno katalitično aktivnostjo |
| AU2013243948A1 (en) * | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9574184B2 (en) * | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| KR102450833B1 (ko) * | 2016-04-15 | 2022-10-05 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 혈우병 a 치료용 유전자 요법 |
| EP3692075A4 (en) | 2017-10-03 | 2022-02-09 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| WO2020012149A1 (en) | 2018-07-13 | 2020-01-16 | Ucl Business Ltd | Glucocerebrosidase gene therapy |
| WO2020012164A1 (en) | 2018-07-13 | 2020-01-16 | Ucl Business Ltd | Glucocerebrosidase gene therapy |
| US20220125892A1 (en) * | 2019-02-01 | 2022-04-28 | OXYRANE UK Ltd. | Glucocerebrosidase polypeptides |
-
2021
- 2021-07-29 EP EP21752123.6A patent/EP4118200B1/en active Active
- 2021-07-29 KR KR1020237007296A patent/KR20230042513A/ko active Pending
- 2021-07-29 CA CA3189801A patent/CA3189801A1/en active Pending
- 2021-07-29 ES ES21752123T patent/ES3057448T3/es active Active
- 2021-07-29 MX MX2023001137A patent/MX2023001137A/es unknown
- 2021-07-29 DK DK21752123.6T patent/DK4118200T3/da active
- 2021-07-29 US US18/017,158 patent/US20240261433A1/en active Pending
- 2021-07-29 PT PT217521236T patent/PT4118200T/pt unknown
- 2021-07-29 HR HRP20251591TT patent/HRP20251591T1/hr unknown
- 2021-07-29 JP JP2023506111A patent/JP2023535808A/ja active Pending
- 2021-07-29 WO PCT/GB2021/051969 patent/WO2022023761A2/en not_active Ceased
- 2021-07-29 CN CN202180066422.7A patent/CN116322744A/zh active Pending
- 2021-07-29 IL IL299811A patent/IL299811A/en unknown
- 2021-07-29 FI FIEP21752123.6T patent/FI4118200T3/fi active
- 2021-07-29 BR BR112023001583A patent/BR112023001583A2/pt unknown
- 2021-07-29 AU AU2021316875A patent/AU2021316875B2/en active Active
- 2021-07-29 EP EP25199900.9A patent/EP4643868A3/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230042513A (ko) | 2023-03-28 |
| WO2022023761A2 (en) | 2022-02-03 |
| EP4643868A3 (en) | 2026-04-08 |
| JP2023535808A (ja) | 2023-08-21 |
| ES3057448T3 (en) | 2026-03-02 |
| FI4118200T3 (fi) | 2025-12-12 |
| CN116322744A (zh) | 2023-06-23 |
| EP4118200B1 (en) | 2025-10-08 |
| IL299811A (en) | 2023-03-01 |
| EP4643868A2 (en) | 2025-11-05 |
| PT4118200T (pt) | 2026-01-08 |
| CA3189801A1 (en) | 2022-02-03 |
| MX2023001137A (es) | 2023-02-22 |
| DK4118200T3 (da) | 2025-12-08 |
| WO2022023761A3 (en) | 2022-03-10 |
| EP4118200A2 (en) | 2023-01-18 |
| US20240261433A1 (en) | 2024-08-08 |
| AU2021316875A1 (en) | 2023-02-23 |
| AU2021316875B2 (en) | 2026-04-02 |
| HRP20251591T1 (hr) | 2026-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001583A2 (pt) | Polipeptídeos de ss-glucocerebrosidase (gcase) modificado, polinucleotídeo, partícula viral e composição | |
| CL2021001624A1 (es) | Composiciones para la reducción de la expresión transgénica específica de drg. | |
| MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
| BR112021024786A2 (pt) | Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada | |
| BR112022014884A2 (pt) | Vetor viral de vaccinia ankara modificado recombinante, vaccinia ankara modificado recombinante, e, método para reduzir ou prevenir uma infecção por coronavírus 2 da síndrome respiratória aguda grave | |
| CO2018005215A2 (es) | Construcciones específicas del hígado para expresión del factor viii | |
| BR112022019501A2 (pt) | Construção de rna auto-amplificante (sarna), sarna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de sarna, construção de sarna e vacina | |
| MX2022010175A (es) | Proteinas de union a flt3 y metodos de uso. | |
| BR112022016992A2 (pt) | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 | |
| BR112019023758A2 (pt) | vírus da doença newcastle e seus usos | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| WO2017053732A3 (en) | Composition and method for treating complement-mediated disease | |
| CL2020001428A1 (es) | Terapia genética para la mucopolisacaridosis iiib. | |
| AR095598A1 (es) | Composiciones y métodos para construcciones quiméricas del virus del dengue en vacunas | |
| CL2023001650A1 (es) | Tratamiento de la enfermedad de danon | |
| BR112021015312A2 (pt) | Polinucleotídeos, partícula viral e composição | |
| MX2020005663A (es) | Terapia genica para mucopolisacaridosis iii a. | |
| BR112018073681A2 (pt) | análogo recombinante isolado de uma alça de fusão da proteína e de flavivírus, análogo recombinante isolado de uma proteína e de flavivírus, sequência de dna ou rna recombinante isolada, sequência de dna recombinante isolada, célula hospedeira, célula hospedeira eucariótica, método de produção de um análogo, composição, composição (vacina) imunogênica capaz de induzir uma resposta imunológica num sujeito inoculado com a referida composição, molécula de ligação, análogo, composição ou molécula de ligação, método para a proteção de um sujeito contra a infecção por um flavivírus, kit de diagnóstico, e kit teste de diagnóstico | |
| AR124736A1 (es) | EFECTO SINÉRGICO DE SMN1 Y miR-23a EN EL TRATAMIENTO DE LA ATROFIA MUSCULAR ESPINAL | |
| BR112018072729B8 (pt) | Ensaio para detectar infecção por flavivírus, cassete de expressão de dna recombinante e genoma de flavivírus recombinante | |
| BRPI0510016B8 (pt) | vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina | |
| BR112019007796A2 (pt) | construção de vacina e seus usos contra infecções causadas por staphylococcus | |
| BR112022019334A2 (pt) | Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células | |
| BR112023023249A2 (pt) | Fator neurotrófico de codificação de vírion aav e usos do mesmo | |
| MX2025000120A (es) | Vaccinia virus oncoliticos y virus recombinantes y metodos de uso de los mismos |